The response to cardiac resynchronization therapy in LMNA cardiomyopathy

Kiran Sidhu, Anna Isotta Castrini, Victoria Parikh, Nosheen Reza, Anjali Owens, Maxime Tremblay-Gravel, Matthew T. Wheeler, Luisa Mestroni, Matthew Taylor, Sharon Graw, Marta Gigli, Marco Merlo, Alessia Paldino, Gianfranco Sinagra, Daniel P. Judge, Hannia Ramos, Olurotimi Mesubi, Emily Brown, Samual Turnbull, Saurabh KumarDarius Roy, Usha B. Tedrow, Long Ngo, Kristina Haugaa, Neal K. Lakdawala

Research output: Contribution to journalArticlepeer-review


Aims: Cardiac implantable electronic device (CIED) therapy is fundamental to the management of LMNA cardiomyopathy due to the high frequency of atrioventricular block and ventricular tachyarrhythmias. We aimed to define the role of cardiac resynchronization therapy (CRT) in impacting heart failure in LMNA cardiomyopathy. Methods and results: From nine referral centres, LMNA cardiomyopathy patients who underwent CRT with available pre- and post-echocardiograms were identified retrospectively. Factors associated with CRT response were identified (defined as improvement in left ventricular ejection fraction [LVEF] ≥5% 6 months post-implant) and the associated impact on the primary outcome of death, implantation of a left ventricular assist device or cardiac transplantation was assessed. We identified 105 patients (mean age 51 ± 10 years) undergoing CRT, including 70 (67%) who underwent CRT as a CIED upgrade. The mean change in LVEF ∼6 months post-CRT was +4 ± 9%. A CRT response occurred in 40 (38%) patients and was associated with lower baseline LVEF or a high percentage of right ventricular pacing prior to CRT in patients with pre-existing CIED. In patients with a European Society of Cardiology class I guideline indication for CRT, response rates were 61%. A CRT response was evident at thresholds of LVEF ≤45% or percent pacing ≥50%. There was a 1.3 year estimated median difference in event-free survival in those who responded to CRT (p = 0.04). Conclusion: Systolic function improves in patients with LMNA cardiomyopathy who undergo CRT, especially with strong guideline indications for implantation. Post-CRT improvements in LVEF are associated with survival benefits in this population with otherwise limited options.

Original languageEnglish (US)
Pages (from-to)685-693
Number of pages9
JournalEuropean Journal of Heart Failure
Issue number4
StatePublished - Apr 2022


  • Cardiac resynchronization therapy
  • Dilated cardiomyopathy
  • Heart failure
  • Lamin A/C

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The response to cardiac resynchronization therapy in LMNA cardiomyopathy'. Together they form a unique fingerprint.

Cite this